The report analyzes development strategies for 347 colorectal cancer drugs in different stages of development. The analysis looks at drug targets and drug target strategies.
Related Articles on Drug Development:
MIT Researcher: Device and Drug Combos Carry Greater Risk, Reward
USC School of Pharmacy Establishes International Center for Regulatory Science
FDA Reports Increase in New Drug Approvals in FY 2011
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
